欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 91sao| av成人免| 精品在线免费播放 | 国产91精品系列在线观看 | 国产水手服19禁在线视频网站 | 欧美成人黄片在线观看 | 国产精品一区一区三区 | 国产欧美成人久久精品蜜桃 | 亚洲制服中文字幕26页 | 亚洲国产精品自在现线让你爽 | 亚洲中文无 | 亚洲免费观看一级 | 日韩熟女激情中 | 男女18禁啪啪无遮挡激烈 | 国产玉足脚交极品网站 | 成人色站| 精品久久久久久亚洲精品 | 亚洲欧美日韩精品一区二区 | 国产大爆乳大爆乳在线播放 | 国产亚洲欧美精品久久久 | 午夜无码一区二区三区在线 | 无码专区在 | 成人乱人伦视频在线观看 | 免费精品无码av片在线观看 | 少妇内射呻吟中文字幕在线 | 九九免费视频网站 | 久久人人爽人人爽大片aw | 中文字幕一区二区三区四区 | 免费中文日本久久 | 国产成人一区二区三区免费视 | 欧美人与牲禽动交精品 | 国产大陆欧美日韩中文 | 亚洲av无码专区国产乱码不卡 | 欧美爆操| 亚洲成a| 成年人com日批软件91 | 一级片中文字幕 | 女人下边被添全过视频 | 国产在线一区二区三区欧美 | 亚洲中文字幕无码久久 | 亚洲日韩国产欧美久久久 |